HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. HilleVax's Goodwill for the quarter that ended in Dec. 2023 was $0.00 Mil. HilleVax's Total Assets for the quarter that ended in Dec. 2023 was $344.43 Mil.
The historical data trend for HilleVax's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Goodwill-to-Asset | - | - | - | - |
HilleVax Quarterly Data | |||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Goodwill-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, HilleVax's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where HilleVax's Goodwill-to-Asset falls into.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
HilleVax's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Goodwill to Asset (A: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 344.434 | |
= |
HilleVax's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Goodwill to Asset (Q: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 344.434 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax (NAS:HLVX) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of HilleVax's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Astrid Borkowski | officer: Chief Medical Officer | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109 |
Nanette Cocero | director | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109 |
Shane Maltbie | officer: Chief Financial Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Gary Dubin | director | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109 |
Jaime Sepulveda | director | C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
Shelley Chu | director | ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110 |
Susan Michele Silbermann | director | C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Julie L. Gerberding | director | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Aditya Kohli | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
David A Socks | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
From GuruFocus
By Value_Insider Value_Insider • 11-11-2022
By sperokesalga sperokesalga • 05-12-2023
By Marketwired • 09-20-2023
By Marketwired • 09-25-2023
By Value_Insider Value_Insider • 11-10-2022
By PurpleRose PurpleRose • 08-15-2022
By sperokesalga sperokesalga • 04-25-2023
By PurpleRose PurpleRose • 08-10-2022
By Ds*** Ds*** • 09-01-2022
By GuruFocus Research • 11-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.